| Project/Area Number |
19406022
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 海外学術 |
|---|
| Research Field |
Hygiene
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
TANAKA Junko Hiroshima University, 大学院・医歯薬学総合研究科, 教授 (70155266)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KATAYAMA Keiko 広島大学, 大学院・医歯薬学総合研究科, 講師 (50304415)
YOSHIZAWA Hiroshi 広島大学, 大学院・医歯薬学総合研究科, 名誉教授 (30109954)
|
|---|
| Research Collaborator |
BUSCH Michael Director California University, Blood System Research Institute, Professor
MERPHY Edward Senior Investigator California University, Blood System Research Institute, Professor
LUDMILA ZENEVSKAIA Kiev Municipal Blood Center, Director
EDWARD Manza Kiev Municipal Blood Center, System administrator
LELIE Nico Novartis Vaccines and Diagnostics SAS, Senior Director Scientific Affairs
CLARKE Anne International Plasma Fractionation Association in Nertherland, Director
SOMANA Svay Ministry of Health of Kingdom of Cambodia, Vice-chief
OLLONE Lim Ministry of Health of Kingdom of Cambodia, Chief
TABUCHI Ayako 広島大学, 大学院・医歯薬学総合研究科, 社会人大学院生
GOMBOJAV Bayasgalan 広島大学, 非常勤研究員
MIZUI Masaaki 広島県血液センター, 部長
MATSUO Junko 広島大学, 大学院・医歯薬学総合研究科, 助教 (70570232)
|
|---|
| Project Period (FY) |
2007 – 2009
|
| Project Status |
Completed (Fiscal Year 2009)
|
| Budget Amount *help |
¥16,900,000 (Direct Cost: ¥13,000,000、Indirect Cost: ¥3,900,000)
Fiscal Year 2009: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2008: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2007: ¥7,540,000 (Direct Cost: ¥5,800,000、Indirect Cost: ¥1,740,000)
|
|---|
| Keywords | 肝がん対策 / HCV抗体陽性率 / 肝がん死亡率 / 肝炎ウイルス罹患率 / 国際情報交換 / アメリカ / ウクライナ共和国 / カンボジア王国 / 日本:アメリカ:ウクライナ:カンボジア王国 / 国際研究者交流 / 日本:アメリカ:ウクライナ:スウェーデン / 日本:アメリカ:ウクライナ |
|---|
| Research Abstract |
We studied to clarify the relativity between the age of developing HCC and the duration of infection with hepatitis viruses based on the data of the prevalence rate of hepatitis viruses and the mortality rate of hepatocellular carcinoma (HCC). We could offer and construct the evidence of the liver cancer control measures in each country through this study results. The hepatitis B surface antigen positivity rate and anti-HCV prevalence and the liver cancer mortality rate according to the age class acquired data from the United States and the Ukraine were calculated. On the other hand, in cooperation with the Kingdom of Cambodia Ministry of Health we began the pilot study in the one of the Asia country, where the detailed survey about hepatitis viral infection has not done yet. We had made the basement to clarify the prevalence rate and the incidence rate of thehepatitis viruses in Asia.
|
